Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ... in the first half of 2025 and will be responsible for its conduct. Post ...

Eli Lilly The world’s biggest pharmaceutical company by market value ... Novo said it would conduct another Phase 3 trial during the first half of 2025 to better determine optimal dosing.

INDIANAPOLIS, Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also ...

After years of preparation, Eli Lilly is on the ... technology to aid those who use Lilly insulins to manage their diabetes," he added. Lilly said it will conduct a phased rollout for the platform ...

During the conference, Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent, delivered a presentation highlighting 2025 as a pivotal year for significantly business growth and concreate steps ...

“And I think law firms are uniquely suited because of their professional code of conduct and the … ethical approaches ... to the Indianapolis Public Schools Board of Commissioners to Eli Lilly and Co.

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...